Genome & Company Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
98
- Stock Symbol
-
314130
- Investments
-
4
- Share Price
-
$2.36
- (As of Friday Closing)
Genome & Company General Information
Description
Genome & Co is a Korean company engaged in researching and developing dietary supplements, cosmeceuticals, and new drugs. Its products pipeline includes immunooncology therapeutic supplement for treatment of immuno-oncology, lung cancer, colorectal cancer, stomach cancer, breast cancer, pancreatic cancer; dietary supplements for treating obesity and diabetes; cosmetics used for acne and atopic dermatitis; and also produces In Virto fertilization medicine.
Contact Information
Website
www.genomecom.co.krCorporate Office
- 8th Floor 35 Pangyo-ro
- Unjung-dong, Bundang-gu
- Seongnam, Gyeonggi
- South Korea
Corporate Office
- 8th Floor 35 Pangyo-ro
- Unjung-dong, Bundang-gu
- Seongnam, Gyeonggi
- South Korea
Genome & Company Timeline
Genome & Company Stock Performance
As of 13-Nov-2026, Genome & Company’s stock price is $2.36. Its current market cap is $107M with 45.2M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.36 | $2.45 | $1.86 - $7.10 | $107M | 45.2M | 429K | -$0.71 |
Genome & Company Financials Summary
As of 30-Jun-2026, Genome & Company has a trailing 12-month revenue of $16.9M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 100,056 | 141,184 | 60,370 | 116,577 |
| Revenue | 16,855 | 17,277 | 20,334 | 10,934 |
| EBITDA | (24,254) | 633 | (15,395) | (35,156) |
| Net Income | (28,500) | (4,517) | (14,740) | (36,304) |
| Total Assets | 79,702 | 100,700 | 100,026 | 125,757 |
| Total Debt | 16,080 | 13,172 | 21,741 | 20,527 |
Genome & Company Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Genome & Company Comparisons
Industry
Financing
Details
Genome & Company Competitors (2)
One of Genome & Company’s 2 competitors is 4D pharma, a Corporation company based in Leeds, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| 4D pharma | Corporation | Leeds, United Kingdom | ||||
| Vedanta Biosciences | Venture Capital-Backed | Cambridge, MA |
Genome & Company Patents
Genome & Company Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024210437-A1 | Anti-bcam antibody and antibody-drug conjugate | Inactive | 04-Apr-2023 | ||
| JP-2026506070-A | Anti-cntn4 antibodies and uses thereof | Pending | 15-Feb-2023 | ||
| AU-2024222562-A1 | Anti-cntn4 antibody and uses thereof | Pending | 15-Feb-2023 | ||
| EP-4667491-A1 | Anti-cntn4 antibody and uses thereof | Pending | 15-Feb-2023 | ||
| US-20260234228-A1 | Anti-cntn4 antibody and uses thereof | Pending | 15-Feb-2023 | C07K16/18 |
Genome & Company Signals
Genome & Company Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Genome & Company Investments & Acquisitions (4)
Genome & Company’s most recent deal was a Merger/Acquisition with Allbloom. The deal was made on 26-Oct-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Allbloom | 26-Oct-2026 | Merger/Acquisition | Distributors/Wholesale | ||
| Scioto Biosciences | 12-Nov-2021 | Later Stage VC | Drug Delivery | ||
| List Biological Labs | 08-Sep-2021 | Merger/Acquisition | BPO/Outsource Services | ||
| Scioto Biosciences | 10-Aug-2020 | Early Stage VC | Drug Delivery |
Genome & Company ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Genome & Company Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| List Biological Labs | Campbell, CA | 1978 |
Genome & Company FAQs
-
When was Genome & Company founded?
Genome & Company was founded in 2015.
-
Where is Genome & Company headquartered?
Genome & Company is headquartered in Seongnam, South Korea.
-
What is the size of Genome & Company?
Genome & Company has 98 total employees.
-
What industry is Genome & Company in?
Genome & Company’s primary industry is Drug Discovery.
-
Is Genome & Company a private or public company?
Genome & Company is a Public company.
-
What is Genome & Company’s stock symbol?
The ticker symbol for Genome & Company is 314130.
-
What is the current stock price of Genome & Company?
As of 13-Nov-2026 the stock price of Genome & Company is $2.36.
-
What is the current market cap of Genome & Company?
The current market capitalization of Genome & Company is $107M.
-
What is Genome & Company’s current revenue?
The trailing twelve month revenue for Genome & Company is $16.9M.
-
Who are Genome & Company’s competitors?
4D pharma and Vedanta Biosciences are competitors of Genome & Company.
-
What is Genome & Company’s annual earnings per share (EPS)?
Genome & Company’s EPS for 12 months was -$0.71.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process